Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of Pseudomonas aeruginosa Biofilm Treatment
Open Access
- 1 November 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (11), 5230-5237
- https://doi.org/10.1128/aac.00617-11
Abstract
Biofilm growth, antibiotic resistance, and mutator phenotypes are key components of chronic respiratory infections by Pseudomonas aeruginosa in cystic fibrosis patients. We examined the dynamics of mutator and antibiotic-resistant populations in P. aeruginosa flow-cell biofilms, using fluorescently tagged PAO1 and PAOMS (mutator [ mutS ] derivative) strains. Two-day-old biofilms were treated with ciprofloxacin (CIP) for 4 days (t4) at 2 μg/ml, which correlated with the mutant prevention concentration (MPC) and provided an AUC/MIC ratio of 384 that should predict therapeutic success. Biofilms were monitored by confocal laser scanning microscopy (CLSM), and the numbers of viable cells and resistant mutants (4- and 16-fold MICs) were determined. Despite optimized pharmacokinetic/pharmacodynamic (PK/PD) parameters, CIP treatment did not suppress resistance development in P. aeruginosa biofilms. One-step resistant mutants (MexCD-OprJ or MexEF-OprN overexpression) were selected for both strains, while two-step resistant mutants (additional GyrA or GyrB mutation) were readily selected only from the mutator strain. CLSM analysis of competition experiments revealed that PAOMS, even when inoculated at a 0.01 proportion, took over the whole biofilm after only 2 days of CIP treatment outnumbering PAO1 by 3 log at t4. Our results show that mutational mechanisms play a major role in biofilm antibiotic resistance and that theoretically optimized PK/PD parameters fail to suppress resistance development, suggesting that the increased antibiotic tolerance driven by the special biofilm physiology and architecture may raise the effective MPC, favoring gradual mutational resistance development, especially in mutator strains. Moreover, the amplification of mutator populations under antibiotic treatment by coselection with resistance mutations is for the first time demonstrated in situ for P. aeruginosa biofilms.This publication has 67 references indexed in Scilit:
- Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm GrowthAntimicrobial Agents and Chemotherapy, 2011
- Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter StudyAntimicrobial Agents and Chemotherapy, 2011
- Efficacy of the Combination of Tobramycin and a Macrolide in an I n V itro Pseudomonas aeruginosa Mature Biofilm ModelAntimicrobial Agents and Chemotherapy, 2010
- Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB MutantsAntimicrobial Agents and Chemotherapy, 2009
- ChronicPseudomonas aeruginosaInfection in Chronic Obstructive Pulmonary DiseaseClinical Infectious Diseases, 2008
- Endogenous oxidative stress produces diversity and adaptability in biofilm communitiesProceedings of the National Academy of Sciences of the United States of America, 2008
- Dynamics of Pseudomonas aeruginosa genome evolutionProceedings of the National Academy of Sciences of the United States of America, 2008
- Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with HypermutationAntimicrobial Agents and Chemotherapy, 2007
- Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal AgentsAntimicrobial Agents and Chemotherapy, 2007
- Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patientsProceedings of the National Academy of Sciences of the United States of America, 2006